SCHEMBL376293

SCHEMBL376293

COC1(Cc2ccccc2C)CCN(c2ccc(C#N)cc2)CC1

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CHRNA10 Q9GZZ6 1/20 0.40
CHRNA9 Q9UGM1 1/20 0.40
KCNH2 Q12809 1/20 0.40
KDM4E B2RXH2 2/20 0.40
TP53 P04637 1/20 0.40
MAPKAPK2 P49137 4/20 0.40
LMNA P02545 1/20 0.39
BCL2L1 Q07817 2/20 0.36
POLB P06746 1/20 0.36
BCL2 P10415 1/20 0.36
EP300 Q09472 1/20 0.35
ALDH1A1 P00352 1/20 0.35
MAPT P10636 1/20 0.35
HSD17B10 Q99714 1/20 0.35
HTR7 P34969 2/20 0.35
CHEK1 O14757 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL376891 0.87 KDM4E (0.45) CHRNA10CHRNA9KCNH2KDM4ETP53
SCHEMBL376704 0.87 CHRNA10 (0.40) CHRNA10CHRNA9KCNH2KDM4ETP53
SCHEMBL376939 0.85 MAPKAPK2 (0.45) CHRNA10CHRNA9KCNH2KDM4ETP53
SCHEMBL381688 0.84 KCNH2 (0.50) CHRNA10CHRNA9KCNH2KDM4ETP53
SCHEMBL377048 0.83 CHRNA10 (0.42) CHRNA10CHRNA9KCNH2KDM4ETP53
SCHEMBL381714 0.80 F2 (0.48) KDM4ELMNABCL2L1BCL2
SCHEMBL376959 0.78 KDM4E (0.49) CHRNA10CHRNA9KCNH2KDM4ETP53
SCHEMBL12126935 0.73 KDM4E (0.53) CHRNA10CHRNA9KCNH2KDM4ETP53
SCHEMBL376862 0.72 CHRNA10 (0.41) CHRNA10CHRNA9KDM4ETP53HTR7
SCHEMBL2962385 0.71 KMT2A (0.38) KDM4ETP53BCL2L1POLBBCL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1765778-B1 N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS ABBOTT LAB (US) 2012-01-25 EP disclosed
US-20100035879-A1 N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES 2010-02-11 US disclosed
US-20100035879-A1 N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES 2010-02-11 US disclosed
US-20100035879-A1 N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES 2010-02-11 US disclosed
US-7585858-B2 N-sulfonylcarboximidamide apoptosis promoters ABBOTT LABORATORIES (US) 2009-09-08 US disclosed
US-20050272744-A1 N-sulfonylcarboximidamide apoptosis promoters ABBVIE INC. 2005-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035879-A1 N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS BAX, BCL2, BAD CHRNA10 4259/4885CHRNA9 4345/4885KCNH2 4251/4885
US-20050272744-A1 N-sulfonylcarboximidamide apoptosis promoters BAX, BCL2, BAD CHRNA10 4259/4885CHRNA9 4345/4885KCNH2 4251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.